NAD+ and its precursors (NMN, NR) in injectable form are research compounds. Injectable NAD+ formulations are not approved for general human administration. All pharmacokinetic data presented here is drawn from published research. UNIK LAB does not provide medical advice.
Most longevity researchers who've spent time on NAD+ already know the oral data. NMN and NR are reasonably well-characterised in terms of oral absorption — several human trials exist, the bioavailability picture is becoming clearer, and the NAD+ elevation in blood is reproducible. What's far less discussed is the pharmacokinetic comparison across administration modes.
The difference between IV NAD+, subcutaneous NAD+, intranasal NAD+, and oral NMN or NR isn't just about delivery preference — it's about entirely different kinetic profiles, different first-pass handling, different tissue distribution patterns, and arguably different research applications.
1. Why Administration Route Matters for NAD+ Research
NAD+ cannot be directly transported across cell membranes in its intact form. This creates an immediate translational problem: how do you study the effects of raising tissue NAD+ levels if you can't deliver NAD+ directly to cells?
- Oral NAD+ precursors (NMN, NR) are absorbed in the gut, converted to NAD+ intracellularly via salvage pathways
- IV NAD+ bypasses first-pass metabolism entirely, achieves maximum plasma concentration rapidly, but faces the same cell entry problem — extracellular NAD+ must be cleaved by ectoenzymes before precursors can re-enter cells
- Subcutaneous NAD+ produces slower, more sustained plasma elevation with different kinetics from IV
- Intranasal NAD+ is investigated specifically for potential CNS delivery via the olfactory pathway
2. The NAD+ Biosynthesis Pathway: Research Context
NAD+ is synthesised via two primary routes in mammalian cells:
- Salvage pathway (primary): Nicotinamide (NAM) → NAMPT → NMN → NAD+. NAMPT is the rate-limiting step and a major drug development target.
- De novo pathway (secondary): Tryptophan → kynurenine pathway → quinolinate → NAD+
- NMN entry: Via SLC12A8 transporter (identified 2019) or converted extracellularly to NR
- NR entry: Via nucleoside transporters → NRK1/2 → NMN → NAD+
3. NAD+ and Sirtuins: Longevity Biology Background
The scientific case for NAD+ in longevity research rests substantially on the sirtuin connection. Sirtuins (SIRT1–7) are NAD+-dependent deacylases — enzymes that use NAD+ as a cofactor to modify proteins involved in gene expression, DNA repair, and metabolic regulation.
Verdin (2014, PMID 24398962, Nat Med) articulated the key mechanistic link: as NAD+ declines with age, sirtuin activity declines proportionally. Lower sirtuin activity is associated with impaired mitochondrial biogenesis (SIRT1/SIRT3), reduced DNA repair capacity (SIRT1/SIRT6), and metabolic inefficiency.
4. Oral Route: NMN and NR Bioavailability Data
Nicotinamide Riboside (NR): Trammell et al. (2016, PMID 27721479, Nat Commun) published the landmark human bioavailability data. Single doses (100–300 mg) produced dose-dependent increases in blood NAD+ metabolites within 1–4 hours. Half-life of the NAD+ elevation was approximately 2–3 hours from peak.
NMN human RCT — muscle insulin sensitivity: Yoshino M et al. (2021, PMID 33888596, Science) conducted a randomised, double-blind, placebo-controlled trial of oral NMN (250 mg/day) in postmenopausal prediabetic women. NMN administration enhanced muscle insulin sensitivity and upregulated expression of genes involved in muscle remodelling — one of the most rigorous human NMN trials published.
NMN older patients: Akasaka et al. (2023, PMID 36443648) demonstrated measurable improvements in skeletal muscle NAD+ levels and physical performance in older adults with type 2 diabetes after 12 weeks of oral NMN.
Key limitation: Most human trials measure blood NAD+ (primarily erythrocytes), not tissue NAD+ in muscle, liver, or brain. Blood NAD+ elevation is a proxy biomarker.
5. Intravenous (IV) Route: Pharmacokinetics and Half-Life
IV NAD+ produces the most rapid and complete systemic distribution. Plasma NAD+ peaks within minutes of IV infusion and achieves concentrations not attainable via oral administration at equivalent doses.
Half-life: Published PK data for IV NAD+ in humans is sparse. Available evidence suggests a plasma half-life of approximately 30–90 minutes, given rapid uptake into erythrocytes and CD38-mediated cleavage to NAM.
CD38 and IV NAD+ handling: CD38 rapidly degrades extracellular NAD+ to cyclic ADPR and NAM. This means IV NAD+ does not arrive at peripheral cells intact — it arrives as a mixture that then re-enters the NAD+ salvage pathway. The net effect on tissue NAD+ from IV vs. oral delivery is not straightforward.
6. Subcutaneous (SC) Route: Absorption Kinetics
Subcutaneous NAD+ represents the most undercharacterised route. The theoretical profile:
- Slower absorption: SC injection creates a depot — peak plasma concentration is lower than IV but sustained longer (estimated 3–6 hours depot effect)
- No first-pass hepatic metabolism: Like IV, bypasses the GI tract and hepatic first-pass effect
- Human data: Not available — SC NAD+ PK data comes only from animal models
7. Intranasal Route: CNS Delivery Considerations
The intranasal route is driven by a specific research question: can NAD+ or its precursors reach the CNS at meaningful concentrations, given the blood-brain barrier (BBB) limitations on NAD+ transport?
The olfactory route can bypass the BBB — the only location where neurons are directly exposed to the nasal environment. As of April 2026, formal pharmacokinetic data for intranasal NAD+ in humans is essentially absent from the peer-reviewed literature. Animal data suggests potential CNS NAD+ elevation, but human translation is not established.
8. Comparative Pharmacokinetics Table: All Four Routes
| Parameter | Oral (NMN/NR) | Intravenous (IV) | Subcutaneous (SC) | Intranasal |
|---|---|---|---|---|
| Time to Cmax | 1–4 hours (NR: Trammell 2016) | Minutes (during infusion) | 30 min–2 hours (estimated) | 15–60 min (olfactory route, animal data) |
| Plasma half-life of elevation | ~2–3 hours (NR); NMN similar | ~30–90 min (NAD+ itself) | Potentially 3–6 hours (depot effect) | Unknown in humans |
| First-pass metabolism | Yes (intestinal + hepatic) | No (direct systemic) | No (bypasses GI/liver) | No (direct CNS access possible) |
| Blood NAD+ elevation | Moderate; dose-dependent | High; dose-dependent | Moderate–high (estimated) | Low systemically; targeted CNS |
| CNS penetration | Limited (BBB restricts NAD+) | Limited (BBB restricts NAD+) | Limited (BBB restricts NAD+) | Potentially higher via olfactory route |
| Human PK data available | Yes (NR: PMID 27721479; NMN: PMID 36443648) | Sparse (oncology context only) | No (animal data only) | No human data |
| Research use status | Research compound; some NMN/NR as supplements | Research compound only | Research compound only | Research compound only |
Data sources: Trammell et al. 2016 (PMID 27721479), Akasaka et al. 2023 (PMID 36443648), Yoshino M et al. 2021 (PMID 33888596), Verdin 2014 (PMID 24398962), published pharmacokinetic modelling from oncology NAD+ depletion studies.
9. What the Data Cannot Tell Us
- Tissue specificity is unknown from blood data. All the human NMN/NR pharmacokinetic data measures blood NAD+ — not muscle, liver, brain, or adipose tissue NAD+.
- The CD38 problem is unresolved. CD38 expression increases with age and inflammation, accelerating NAD+ degradation. Elevated CD38 in aged subjects could blunt the tissue NAD+ response to any administration route.
- Sirtuin activation from supplementation is indirect. Blood NAD+ elevation doesn't tell us whether intracellular NAD+ in relevant tissues increased sufficiently to alter sirtuin activity.
- Precursor competition effect. NAM, the downstream metabolite, is itself an inhibitor of sirtuins at high concentrations — aggressive supplementation could paradoxically accumulate NAM and inhibit the very enzymes it was supposed to activate.
For the mechanistic review of NAD+/sirtuin biology, see our NAD+ longevity research overview.
10. NAD+ Research Compound Status and Regulatory Context
- Injectable NAD+ (IV and SC): Not approved pharmaceutical products in most jurisdictions. Require IRB or Ethics Committee approval and appropriate clinical trial oversight. Supplied by UNIK LAB exclusively for laboratory and preclinical research use.
- Oral NMN: The FDA has indicated that NMN cannot be marketed as a dietary supplement in the USA under current regulations (2022 guidance), though NR remains available in many jurisdictions.

11. FAQ: Frequently Asked Questions
What is the difference between NAD+ and NMN?
NAD+ (nicotinamide adenine dinucleotide) is the active coenzyme. NMN (nicotinamide mononucleotide) is a direct biosynthetic precursor — one step upstream of NAD+ in the salvage pathway. Cells convert NMN to NAD+ via NMNAT enzymes. Injectable NAD+ delivers the molecule directly but still requires cell membrane transport mechanisms before becoming intracellularly active.
Why would researchers use injectable NAD+ instead of oral NMN?
The primary research rationale is to bypass first-pass metabolism, achieve higher and more rapid plasma NAD+ concentrations, and avoid intestinal conversion steps that complicate interpretation of oral administration studies. Injectable routes are necessary for pharmacokinetic studies requiring precise control over systemic NAD+ exposure.
Is IV NAD+ more effective than oral NMN for raising tissue NAD+ levels?
This is not established. While IV NAD+ achieves higher and faster plasma peaks, the CD38 ectoenzyme rapidly degrades extracellular NAD+. The net tissue NAD+ elevation from IV vs. oral precursors has not been directly compared in a controlled human study — a genuine gap in the research literature.
What role does the blood-brain barrier play in NAD+ research?
The BBB severely restricts direct NAD+ transport into the CNS. Brain NAD+ is maintained via in situ biosynthesis from smaller precursors. Intranasal delivery is being investigated as a way to bypass the BBB via the olfactory pathway, but no formal human pharmacokinetic data is currently available.
How is NR different from NMN?
NR enters cells via nucleoside transporters and is converted to NMN by NRK1/2 kinases, then to NAD+. NMN enters via the SLC12A8 transporter or is first converted to NR extracellularly. NR has more established human bioavailability data (Trammell 2016, PMID 27721479). Both ultimately raise cellular NAD+ through the salvage pathway.
Are injectable NAD+ preparations available as supplements?
No. Injectable NAD+ formulations are not approved dietary supplements in any major jurisdiction. They are supplied exclusively as research compounds for laboratory and preclinical use.
Referenced Studies
- Trammell SA, Schmidt MS et al. “Nicotinamide riboside is uniquely and orally bioavailable in mice and humans.” Nat Commun. 2016. PMID 27721479
- Yoshino M et al. “Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.” Science. 2021. PMID 33888596
- Akasaka H et al. “Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance.” Geriatr Gerontol Int. 2023. PMID 36443648
- Verdin E. “The many faces of sirtuins: Coupling of NAD metabolism, sirtuins and lifespan.” Nat Med. 2014. PMID 24398962
- Trammell SA, Weidemann BJ et al. “Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice.” Sci Rep. 2016. PMID 27230286
Available from UNIK LAB
NAD+ 500mg€79
Research-grade NAD+ 500mg · HPLC verified ≥98% · COA included · 48h EU/UK dispatch
